Subject: CIIX Increases Exposure to International Investors in Germany

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
CIIX Increases Exposure to International Investors in Germany
Hot Stock to WatchHot Stock to Watch

Company:, Inc. (OTCQB: CIIX)


Price: 1.195

Change (%): - 0.06 (4.78)

Volume: 42,809
CIIX Chart to Attend 'Invest 2017' Exhibition in Stuttgart, Germany

SAN GABRIEL, California, April 5, 2017 /PRNewswire/ - (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announced that it will attend the ‘Invest 2017’ exhibition in Stuttgart, Germany which will take place on April 7-8, 2017. Invest 2017 is the leading trade fair and congress for finance and investment in Germany, and provides CIIX the opportunity to introduce its media and nutritional hemp companies, and to German investors.

Invest 2017 is considered to be the No. 1 meeting point for the finance and investment sector in Germany. As one of the largest financial sector events in the Germany, it attracted more than 12,000 visitors and 144 exhibitors in 2016. Many private and institutional investors use the platform to obtain information, compare assets, and invest, while exhibitors have the opportunity to generate interest in raising investment capital for their ventures.

“I am delighted that CIIX is invited to attend Invest 2017 as an exhibitor. This exhibition provides CIIX a valuable opportunity to introduce our nutritional hemp business to the German financial sector and meet numerous potential investors,” says Warren Wang, founder and CEO of CIIX. “In March 2017, an act to legalize the use of cannabis for medicinal purposes was passed by the German parliament. The recent approval of medical cannabis will be good for the development of the hemp-based CBD market in Germany.”

As a result of the ‘cannabis as medicine’ law, people with severe illnesses in Germany can legally obtain drugs containing cannabis, with a prescription. According to Germany’s Federal Ministry of Health, doctors will also be able to prescribe marijuana or cannabis to patients for whom the drug could alleviate symptoms such as chronic pain or nausea, or who may see a positive effect on their disease progression.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks